Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 935 participants.
Also called NCT04273945
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 935 participants
- Sponsor
- Registry
-
NCT04273945 -
2019-002533-11 -
2024-515669-32-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04273945. Randomized; triple masking; primary purpose treatment. Start 2020-06-30 (actual); primary completion 2025-10-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
- Acronym
- UNISUS
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Macitentan 10 mg
- Intervention (Drug)
- Macitentan 37.5 mg
- Intervention (Drug)
- Macitentan 75 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct04273945- Content hash
e61a0d2277800ba7625e11d7023e1a65bb2b86b32997e0a5c8130c6e3558d666